Bausch + Lomb Corporation BLCO
Set alert
At close
Pre-market · Nov 2, 7:00 AM ET
- YTD
- +17.10%
- 1 year
- +32.10%
- Open
- 20.85
- Prev close
- 20.40
- Mkt cap
- 7.15B
- Vol
- 1.43M
- Avg vol
- 554.75K
- EPS
- -0.32
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.83
- High
- 20.85
- Forward P/E
- 16.72
- Beta
- 0.00
- Short ratio
- 5.12
- Inst. own
- 11.24%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 17, 2027
- 50-d avg
- 17.29
- 200-d avg
- 16.66
- 1y target
- 21.64
5Y chart
Events in this range
- Oct 29, 2025Earnings: 0.18; estimate 0.16; surprise 12.5%
- Feb 18, 2026Earnings: 0.32; estimate 0.35; surprise -8.57%
- Apr 29, 2026Earnings: 0.08; estimate 0.06; surprise 33.33%
- Jul 29, 2026Earnings: 0.16; estimate 0.1544; surprise 3.63%
- Sep 15, 2026Rating: Needham · Hold → Hold
- Oct 7, 2026Rating: Barclays · — → Overweight
- Oct 28, 2026Earnings: 0.34; estimate 0.2145; surprise 58.51%
- Oct 29, 2026Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Oct 29, 2026Rating: RBC Capital · Outperform → Outperform
- Oct 29, 2026Rating: Citigroup · Buy → Buy
- Oct 29, 2026Rating: JP Morgan · Neutral → Neutral
Signals (87)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Oct 26, 2026 | 1 week ago |
| SMA: Bullish | Oct 19, 2026 | 2 weeks ago |
| MACD: Buy Signal | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 12, 2026 | 3 weeks ago |
| MACD: Sell Signal | Oct 12, 2026 | 3 weeks ago |
| SMA: Bullish | Oct 5, 2026 | 4 weeks ago |
| SMA: Bearish | Sep 14, 2026 | 1 month ago |
| SMA: Bullish | Jul 27, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| MACD: Buy Signal | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jun 29, 2026 | 4 months ago |
| SMA: Bullish | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bearish | Apr 20, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bullish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 16, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 9, 2026 | 7 months ago |
| SMA: Bearish | Mar 2, 2026 | 8 months ago |
| SMA: Bullish | Feb 2, 2026 | 9 months ago |
| SMA: Bearish | Jan 26, 2026 | 9 months ago |
| SMA: Bullish | Nov 24, 2025 | 11 months ago |
| SMA: Bearish | Nov 17, 2025 | 11 months ago |
| SMA: Bullish | Nov 3, 2025 | 12 months ago |
| SMA: Bearish | Oct 27, 2025 | 1 year ago |
| SMA: Bullish | Oct 13, 2025 | 1 year ago |
| SMA: Bearish | Oct 6, 2025 | 1 year ago |
| SMA: Bullish | Sep 29, 2025 | 1 year ago |
| SMA: Bearish | Sep 22, 2025 | 1 year ago |
| SMA: Bullish | Aug 11, 2025 | 1 year ago |
| SMA: Bearish | Jul 28, 2025 | 1 year ago |
| SMA: Bullish | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jun 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 23, 2025 | 1 year ago |
| SMA: Bearish | Jun 16, 2025 | 1 year ago |
| SMA: Bullish | Jun 9, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| SMA: Bearish | Jan 6, 2025 | 1 year ago |
| SMA: Bearish | Dec 9, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 9, 2024 | 1 year ago |
| SMA: Bullish | Nov 25, 2024 | 1 year ago |
| SMA: Bearish | Nov 18, 2024 | 1 year ago |
| SMA: Bullish | Sep 16, 2024 | 2 years ago |
| SMA: Bullish | Sep 16, 2024 | 2 years ago |
| SMA: Bearish | Sep 9, 2024 | 2 years ago |
| SMA: Bearish | Sep 2, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bullish | Jul 8, 2024 | 2 years ago |
| SMA: Bearish | Jun 24, 2024 | 2 years ago |
| SMA: Bullish | May 27, 2024 | 2 years ago |
| MACD: Buy Signal | May 27, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 22, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| SMA: Bearish | Apr 8, 2024 | 2 years ago |
| SMA: Bullish | Mar 18, 2024 | 2 years ago |
| SMA: Bearish | Mar 11, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| SMA: Bullish | Feb 19, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 19, 2024 | 2 years ago |
| SMA: Bearish | Jan 8, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 8, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 25, 2023 | 2 years ago |
| SMA: Bearish | Nov 6, 2023 | 2 years ago |
| SMA: Bullish | Oct 30, 2023 | 3 years ago |
| SMA: Bearish | Aug 21, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 7, 2023 | 3 years ago |
| SMA: Bearish | Jul 31, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 24, 2023 | 3 years ago |
| SMA: Bullish | Apr 17, 2023 | 3 years ago |
| SMA: Bearish | Apr 10, 2023 | 3 years ago |
| MACD: Sell Signal | Apr 10, 2023 | 3 years ago |
| MACD: Buy Signal | Apr 3, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| SMA: Bullish | Mar 27, 2023 | 3 years ago |
| MACD: Sell Signal | Mar 20, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bearish | Mar 6, 2023 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| SMA: Bullish | Dec 26, 2022 | 3 years ago |
| MACD: Buy Signal | Dec 26, 2022 | 3 years ago |
| SMA: Bearish | Dec 12, 2022 | 3 years ago |
| SMA: Bullish | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Sep 26, 2022 | 4 years ago |
| SMA: Bullish | Sep 5, 2022 | 4 years ago |
| SMA: Bearish | Aug 15, 2022 | 4 years ago |
| SMA: Bullish | Aug 8, 2022 | 4 years ago |
Key statistics
- Market cap
- 7.14B
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 16.72
- PEG ratio
- 0.89
- Price / sales
- 1.32
- Price / book
- 1.10
- EPS (TTM)
- -0.32
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -2.05%
- Revenue (TTM)
- 5.42B
- Revenue growth
- 7.30%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 357.50M
- Short % of float
- 5.55%
- 50-day average
- 17.29
- 200-day average
- 16.66
Analyst view
Consensus: buy
- Target (low)
- 18.00
- Target (mean)
- 21.64
- Target (high)
- 26.00
- Strong buy2
- Buy5
- Hold7
- Sell0
- Strong sell1
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate 0.37246.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | 0.34 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.2145 | 0.34 | +0.13 | +58.51% |
| Jul 29, 2026 | Jun 30, 2026 | 0.1544 | 0.16 | +0.01 | +3.63% |
| Apr 29, 2026 | Mar 31, 2026 | 0.06 | 0.08 | +0.02 | +33.33% |
| Feb 18, 2026 | Dec 31, 2025 | 0.35 | 0.32 | -0.03 | -8.57% |
| Oct 29, 2025 | Sep 30, 2025 | 0.16 | 0.18 | +0.02 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 29, 2026 | Citigroup | main | Buy | Buy |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 29, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 7, 2026 | Barclays | init | — | Overweight |
| Sep 15, 2026 | Needham | reit | Hold | Hold |
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Canada
- Website
- bausch.com
News
- HC Wainwright & Co. Downgrades Bausch & Lomb to Neutral, Raises Price Target to $22
- JP Morgan Maintains Neutral on Bausch & Lomb, Raises Price Target to $22
- RBC Capital Maintains Outperform on Bausch & Lomb, Raises Price Target to $23
- Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19
- Bausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient Education
- What Bausch + Lomb (BLCO) Said on Its Q3 Earnings Call
- Bausch + Lomb Corporation (BLCO) Q3 2026 Earnings Call Transcript
- Bausch + Lomb (BLCO) Surpasses Q3 Earnings and Revenue Estimates
- Bausch & Lomb Q3 Adj. EPS $0.34 Beats $0.22 Estimate, Sales $1.375B Beat $1.373B Estimate
- Bausch & Lomb Raises FY2026 Sales Guidance from $5.440B-$5.540B to $5.450B-$5.550B vs $5.496B Est
Your note
Sign in to keep a note on BLCO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAILEY AMBROSE ROBERT DOUGLAS J.D. | Officer | Stock Award(Grant) | Aug 4, 2026 | 264,241 |
| BERNIER NATHALIE D | Director | Stock Award(Grant) | May 25, 2026 | 85,505 |
| BONNEFOY LUC | Officer | Stock Award(Grant) | Aug 4, 2026 | 103,801 |
| ELDESSOUKY OSAMA A | Chief Financial Officer | Stock Award(Grant) | Aug 4, 2026 | 393,527 |
| ELDESSOUKY SAM | Chief Financial Officer | Purchase | Mar 5, 2026 | 407,130 |
| HASHAD YEHIA | Officer | Stock Award(Grant) | Aug 4, 2026 | 187,350 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Icahn Carl C | 0.98% | 3,500,000 | 69.86M | Jun 29, 2026 |
| Deutsche Bank AG | 0.96% | 3,423,046 | 68.32M | Jun 29, 2026 |
| Oaktree Capital Management LP | 0.96% | 3,441,042 | 68.68M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 0.93% | 3,323,021 | 66.33M | Jun 29, 2026 |
| Davidson Kempner Capital Management LP | 0.88% | 3,158,972 | 63.05M | Jun 29, 2026 |
| Goldentree Asset Management LP | 0.74% | 2,660,508 | 53.10M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price High Yield Fund, Inc. | 0.23% | 837,050 | 16.71M | Aug 30, 2026 |
| TR PRICE-Price (T.Rowe) U.S. High Yield Trust | 0.13% | 454,220 | 9.07M | Jun 29, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Dynamic Credit Fd. | 0.06% | 204,491 | 4.08M | Jun 29, 2026 |
| T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F | 0.06% | 218,211 | 4.36M | Aug 30, 2026 |
| Unified Series Trust-BALLAST SMALL/MID CAP ETF | 0.04% | 147,837 | 2.95M | Jun 29, 2026 |
| Gabelli Healthcare & WellnessRx Trust | 0.04% | 144,000 | 2.87M | Sep 29, 2026 |